BETA BLOCKER DOSAGE AND USE OVER TIME IN THE SYSTOLIC HEART FAILURE TREATMENT WITH THE IF INHIBITOR IVABRADINE TRIAL (SHIFT) STUDY

Background: In the SHIFT study, ivabradine, a novel selective inhibitor of the cardiac pacemaker f-current (If) that lowers heart rate, showed significant reduction in cardiovascular mortality or hospitalizations for worsening heart failure vs placebo in patients with chronic systolic heart failure,...

Full description

Saved in:
Bibliographic Details
Published inJournal of the American College of Cardiology Vol. 65; no. 10; p. A872
Main Authors Borer, Jeffrey S., Swedberg, Karl, Komajda, Michel, Ford, Ian, Tavazzi, Luigi, Boehm, Michael, Dominjon, Fabienne, Maya, Juan, Wu, Yuna
Format Journal Article
LanguageEnglish
Published New York Elsevier Inc 17.03.2015
Elsevier Limited
Subjects
Cardiology
Cardiovascular
Drug therapy
Heart failure
Older people
Online AccessGet full text
ISSN0735-1097
1558-3597
DOI10.1016/S0735-1097(15)60872-5

Cover

More Information
Summary:Background: In the SHIFT study, ivabradine, a novel selective inhibitor of the cardiac pacemaker f-current (If) that lowers heart rate, showed significant reduction in cardiovascular mortality or hospitalizations for worsening heart failure vs placebo in patients with chronic systolic heart failure, when added to standard therapy, including beta blockers (BB).
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ISSN:0735-1097
1558-3597
DOI:10.1016/S0735-1097(15)60872-5